Norwegian Cruise Line Holdings vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Three-brand cruise operator (Norwegian, Oceania, Regent) with $9.8B FY2024 revenue; "Charting the Course" targets $2/share EPS by 2026; Norwegian Aqua launching 2025; post-COVID debt reduction focus.
About
Norwegian Cruise Line Holdings is one of the world's leading cruise companies, operating three distinct brands across the full spectrum of ocean cruising—Norwegian Cruise Line (contemporary), Oceania Cruises (premium), and Regent Seven Seas Cruises (ultra-luxury)—headquartered in Miami, Florida and trading on NYSE (NCLH). Under CEO Harry Sommer, who assumed leadership in January 2023, the company generated approximately $9.8 billion in revenues for FY2024, representing a complete post-pandemic recovery from COVID-era shutdown losses. Norwegian Cruise Line Holdings launched its "Charting the Course" strategic plan in 2024, targeting $2 per share in adjusted EPS by 2026 and $3 per share by 2028, with operational priorities including revenue yield improvement, cost efficiency, and leverage reduction from the substantial debt accumulated during the pandemic.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.